◀ Back to HDAC2

HDAC2 — PCNA

Text-mined interactions from Literome

Hatjiharissi et al., Cancer Res 2007 (Waldenstrom Macroglobulinemia) : Other proteins up-regulated by > 1.3-fold included cyclin dependent kinases, apoptosis regulators, and histone deacetylases (HDAC)
Veliz et al., Cancer Control 2012 (Leukemia, Lymphocytic, Chronic, B-Cell...) : These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab, cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors, and histone deacetylase inhibitors
Brett et al., Current treatment options in oncology 2013 : Similarly, cell cycle inhibitors targeting cyclin dependent kinases as well as HDAC inhibitors have shown promise in early studies